Company Description
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders.
This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease.
The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.
This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers.
It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies.
The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018.
Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
| Country | United States |
| Founded | 2002 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 7,700 |
| CEO | Chirag K. Patel |
Contact Details
Address: 400 Crossing Boulevard Bridgewater, New Jersey 08807 United States | |
| Phone | 908 947 3120 |
| Website | amneal.com |
Stock Details
| Ticker Symbol | AMRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001723128 |
| CUSIP Number | 03168L105 |
| ISIN Number | US03168L1052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chirag K. Patel | Co-Founder, Co-Chief Executive Officer, President and Director |
| Chintu Patel R.Ph. | Co-Founder, Co-Chief Executive Officer and Director |
| Anastasios G. Konidaris | Executive Vice President and Chief Financial Officer |
| Jason B. Daly Esq. | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Nikita Shah | Executive Vice President and Chief Human Resources Officer |
| Andrew S. Boyer | Executive Vice President and Chief Commercial Officer of Generics |
| Anthony DiMeo | Head of Investor Relations |
| Gregory Sgammato | Senior Vice President of Corporate Development |
| Pranav Mehta | Senior Vice President of Strategic Sourcing and Supply Management |
| Dr. Sanjay Kumar Jain Ph.D. | Chief Quality Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 22, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 14, 2024 | 10-K | Annual Report |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 10, 2024 | 8-K | Current Report |
| Jan 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 3, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 27, 2023 | CERT | Certification by an exchange approving securities for listing |